Our Plans

We aim to research and develop safe effective migraine products in New Zealand, and export them world wide to help migraine sufferers everwhere.

Mahana is committed to an ongoing program of advanced research, supporting the development of safe, effective medicinal cannabis migraine products, targeting all areas of the migraine life cycle. Our research into genetics, high-yielding chemotype strains, new and novel delivery systems, along with neuropathic clinical trials, all play their part in developing our leading cannabis migraine products.

New Zealand-grown cannabis has enormous therapeutic migraine potential. It’s the world’s most pharmacologically active plant, containing hundreds of beneficial compounds, including cannabinoids and terpenes. The efficacy of both terpenoids and cannabinoids in treating a variety of both severe episodic and chronic daily migraine, is an area of medicine that demands thorough study.

We are harnessing cannabis genetics to create novel migraine medicines from unique cultivars. We aim to be the global leader in migraine therapy research, development and commercialisation.